Lake Street analyst Frank Takkinen reiterated a Buy rating on Apyx Medical (APYX – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $3.15.
Takkinen covers the Healthcare sector, focusing on stocks such as NeuroPace, Science 37, and Apyx Medical. According to TipRanks, Takkinen has an average return of -11.8% and a 30.48% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apyx Medical with a $7.17 average price target.
See the top stocks recommended by analysts >>
Based on Apyx Medical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $13.57 million and a GAAP net loss of $994 thousand. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $5.43 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical (APYX) Company Description:
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Read More on APYX:
